All In Biotech

Drug Trial Radar · NCT00978211

DOTA-TOC in Metastasized Neuroendocrine Tumors

Phase II Study of [90Y-DOTA]-TOC and [177Lu-DOTA]-TOC in Metastasized Neuroendocrine Tumors

Last checked: Nov 19, 2026Latest source record: Aug 7, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

1,499

Actual

Start

Sep 1997

Primary completion

Sep 2013

Study completion Dec 2013

Sponsor

Lead sponsor
University Hospital, Basel, SwitzerlandAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 16, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The investigators aim to explore the efficacy of \[90Y-DOTA\]-TOC and \[177LuDOTA\]-TOC therapy in advanced neuroendocrine cancer. Therefore, the investigators assess response, survival and long-term safety profile of systemic \[90Y-DOTA\]-TOC and \[177LuDOTA\]-TOC treatment in metastasized neuroendocrine cancer patients. Adverse events are assessed according to the criteria of the National Cancer Institute. Survival analyses are performed using multiple regression models.

Conditions

  • Neuroendocrine Tumors

Interventions

  • DOTA-TOC TreatmentDrug

    Intravenous injections of DOTA-TOC. Repeated treatment cycles for responders, except in case of * renal toxicity * loss of patient transferability or * denial of further treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ResponseTime frame: 3 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospital

    Basel, Canton of Basel-City, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.